SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Marteau P)
 

Sökning: WFRF:(Marteau P) > Lindgren Stefan > Combined oral and e...

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

Marteau, P (författare)
Probert, CS (författare)
Lindgren, Stefan (författare)
Lund University,Lunds universitet,Gastroenterologi,Forskargrupper vid Lunds universitet,Enheten för kroniska inflammatoriska och degenerativa sjukdomar,Gastroenterology,Lund University Research Groups,Chronic Inflammatory and Degenerative Diseases Research Unit
visa fler...
Gassul, M (författare)
Tan, TG (författare)
Dignass, A (författare)
Befrits, R (författare)
Karolinska Institutet
Midhagen, G (författare)
Rademaker, J (författare)
Foldager, M (författare)
visa färre...
 (creator_code:org_t)
BMJ, 2005
2005
Engelska.
Ingår i: Gut. - : BMJ. - 1468-3288 .- 0017-5749. ; 54:7, s. 960-965
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background and aims: Oral aminosalicylates are well established in the treatment of active mild/moderate ulcerative colitis (UC) when the disease is extensive (that is, beyond the splenic flexure). The majority of clinical symptoms relate to disease activity in the distal part of the colon and therefore this study was designed to investigate if adding a mesalazine enema to oral mesalazine has additional benefit for patients with extensive mild/moderate active UC. Methods: A randomised double blind study was performed in 127 ambulatory patients. All received 4 g/day (twice daily dosing) oral mesalazine for eight weeks. During the initial four weeks, they additionally received an enema at bedtime containing 1 g of mesalazine or placebo. Disease activity was assessed using the ulcerative colitis disease activity index, with clinical and endoscopic signs at four and eight weeks. Results: Remission was obtained in 44% (95% confidence interval (CI) 31%, 58%) of the mesalazine enema group (Me) and in 34% (95% CI 21%, 49%) of the placebo enema group (Pl) at four weeks (p = 0.31) and in 64% (95% CI 50%, 76%) of the Me group versus 43% (95% CI 28%, 58%) of the Pl group at eight weeks (p = 0.03). Improvement was obtained in 89% (95% CI 78%, 96%) of the Me group versus 62% (95% CI 46%, 75%) of the Pl group at four weeks (p = 0.0008) and in 86% (95% CI 75%, 94%) of the Me group versus 68% (95% CI 53%, 81%) of the Pl group at eight weeks (p = 0.026). Conclusion: In patients with extensive mild/moderate active UC, the combination therapy is superior to oral therapy. It is safe, well accepted, and may be regarded as firstline treatment.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

  • Gut (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy